BACKGROUND: In 2010, Niger and other meningitis belt countries introduced a meningococcal serogroup A conjugate vaccine (MACV). We describe the epidemiology of bacterial meningitis in Niger from 2010 to 2018. METHODS: Suspected and confirmed meningitis cases from January 1, 2010 to July 15, 2018 were obtained from national aggregate and laboratory surveillance. Cerebrospinal fluid specimens were analyzed by culture and/or polymerase chain reaction. Annual incidence was calculated as cases per 100 000 population. Selected isolates obtained during 2016-2017 were characterized by whole-genome sequencing. RESULTS: Of the 21 142 suspected cases of meningitis, 5590 were confirmed: Neisseria meningitidis ([Nm] 85%), Streptococcus pneumoniae ([Sp] 13%), and Haemophilus influenzae ([Hi] 2%). No NmA cases occurred after 2011. Annual incidence per 100 000 population was more dynamic for Nm (0.06-7.71) than for Sp (0.18-0.70) and Hi (0.01-0.23). The predominant Nm serogroups varied over time (NmW in 2010-2011, NmC in 2015-2018, and both NmC and NmX in 2017-2018). Meningococcal meningitis incidence was highest in the regions of Niamey, Tillabery, Dosso, Tahoua, and Maradi. The NmW isolates were clonal complex (CC)11, NmX were CC181, and NmC were CC10217. CONCLUSIONS: After MACV introduction, we observed an absence of NmA, the emergence and continuing burden of NmC, and an increase in NmX. Niger's dynamic Nm serogroup distribution highlights the need for strong surveillance programs to inform vaccine policy. Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: In 2010, Niger and other meningitis belt countries introduced a meningococcal serogroup A conjugate vaccine (MACV). We describe the epidemiology of bacterial meningitis in Niger from 2010 to 2018. METHODS: Suspected and confirmed meningitis cases from January 1, 2010 to July 15, 2018 were obtained from national aggregate and laboratory surveillance. Cerebrospinal fluid specimens were analyzed by culture and/or polymerase chain reaction. Annual incidence was calculated as cases per 100 000 population. Selected isolates obtained during 2016-2017 were characterized by whole-genome sequencing. RESULTS: Of the 21 142 suspected cases of meningitis, 5590 were confirmed: Neisseria meningitidis ([Nm] 85%), Streptococcus pneumoniae ([Sp] 13%), and Haemophilus influenzae ([Hi] 2%). No NmA cases occurred after 2011. Annual incidence per 100 000 population was more dynamic for Nm (0.06-7.71) than for Sp (0.18-0.70) and Hi (0.01-0.23). The predominant Nm serogroups varied over time (NmW in 2010-2011, NmC in 2015-2018, and both NmC and NmX in 2017-2018). Meningococcal meningitis incidence was highest in the regions of Niamey, Tillabery, Dosso, Tahoua, and Maradi. The NmW isolates were clonal complex (CC)11, NmX were CC181, and NmC were CC10217. CONCLUSIONS: After MACV introduction, we observed an absence of NmA, the emergence and continuing burden of NmC, and an increase in NmX. Niger's dynamic Nm serogroup distribution highlights the need for strong surveillance programs to inform vaccine policy. Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
zzm321990 Neisseria meningitidiszzm321990 ; Niger; epidemiology; meningitis belt
Authors: C V Broome; M A Rugh; A A Yada; L Giat; H Giat; J M Zeltner; W R Sanborn; D W Fraser Journal: Bull World Health Organ Date: 1983 Impact factor: 9.408
Authors: Alicia R Feagins; Jeni Vuong; Katya Fernandez; Berthe M Njanpop-Lafourcade; Jason M Mwenda; Yibayiri Osee Sanogo; Mariétou F Paye; Sarah K Payamps; Leonard Mayer; Xin Wang Journal: J Infect Dis Date: 2019-10-31 Impact factor: 5.226
Authors: Catherine H Bozio; Jeni Vuong; E Kainne Dokubo; Mosoka P Fallah; Lucy A McNamara; Caelin C Potts; John Doedeh; Miatta Gbanya; Adam C Retchless; Jaymin C Patel; Thomas A Clark; Henry Kohar; Thomas Nagbe; Peter Clement; Victoria Katawera; Nuha Mahmoud; Harouna M Djingarey; Anne Perrocheau; Dhamari Naidoo; Mardia Stone; Roseline N George; Desmond Williams; Alex Gasasira; Tolbert Nyenswah; Xin Wang; LeAnne M Fox Journal: Lancet Infect Dis Date: 2018-10-15 Impact factor: 25.071
Authors: Anna M Molesworth; Luis E Cuevas; Stephen J Connor; Andrew P Morse; Madeleine C Thomson Journal: Emerg Infect Dis Date: 2003-10 Impact factor: 6.883
Authors: Jaymin C Patel; Heidi M Soeters; Alpha Oumar Diallo; Brice W Bicaba; Goumbi Kadadé; Assétou Y Dembélé; Mahamat A Acyl; Christelle Nikiema; Clement Lingani; Cynthia Hatcher; Anna M Acosta; Jennifer D Thomas; Fabien Diomande; Stacey Martin; Thomas A Clark; Richard Mihigo; Rana A Hajjeh; Catherine H Zilber; Flavien Aké; Sarah A Mbaeyi; Xin Wang; Jennifer C Moisi; Olivier Ronveaux; Jason M Mwenda; Ryan T Novak Journal: J Infect Dis Date: 2019-10-31 Impact factor: 5.226
Authors: Usman N Ikumapayi; Philip C Hill; Ilias Hossain; Yekini Olatunji; Malick Ndiaye; Henry Badji; Ahmed Manjang; Rasheed Salaudeen; Lamin Ceesay; Richard A Adegbola; Brian M Greenwood; Grant A Mackenzie Journal: PLoS One Date: 2022-08-10 Impact factor: 3.752